What is Pharmacogenomic Testing?
Pharmacogenomics (PGx) studies how genetic variation affects a person's response to medications. Variants in metabolising enzymes, drug transporters and HLA types can predict whether a drug will work as expected, whether standard dosing is appropriate, and whether someone is at elevated risk of an adverse reaction. This panel is scoped strictly to genes with established CPIC or PharmGKB guidance.
Drug Metabolism
How quickly drugs are activated or cleared
Drug Efficacy
Likelihood a medication will achieve its intended effect
Adverse Reactions
Risk of hypersensitivity or toxicity events
Genes Analysed
The panel covers clinically relevant pharmacogenes including:
CYP2D6
Metabolism of ~25% of prescribed drugs (antidepressants, opioids, antipsychotics)
CYP2C19
Clopidogrel, PPIs, SSRIs activation/metabolism
CYP2C9
Warfarin, NSAIDs, phenytoin metabolism
CYP3A5
Tacrolimus dosing in transplant recipients
CYP4F2
Vitamin K metabolism, warfarin response
VKORC1
Warfarin sensitivity
TPMT
Thiopurine toxicity risk (azathioprine, mercaptopurine)
NUDT15
Thiopurine toxicity risk
DPYD
Fluoropyrimidine (5-FU, capecitabine) toxicity
SLCO1B1
Statin-induced myopathy risk
UGT1A1
Irinotecan and atazanavir metabolism
NAT2
Isoniazid acetylation
G6PD
Haemolysis risk with oxidative drugs
HLA-A
Hypersensitivity (e.g. carbamazepine)
HLA-B
Severe cutaneous reactions (abacavir, allopurinol, carbamazepine)
IFNL3
Hepatitis C antiviral response
And other PharmGKB / CPIC-recognised genes where validated prescribing guidance exists.
What's on Your Report?
- Metaboliser status (poor, intermediate, normal, rapid, ultra-rapid) for each gene
- Drug–gene interaction summaries aligned to CPIC guidelines
- Flags for drugs requiring dose adjustment or avoidance
- HLA-linked hypersensitivity risk markers
- Plain-language explanations suitable for sharing with prescribing clinicians
Important Limitations
PGx results inform prescribing decisions but do not replace clinical judgement. Never start, stop or change a medication based on these results without consulting a qualified prescriber.
- • Covers only pharmacogenes with established CPIC/PharmGKB guidance
- • No lifestyle, ancestry or non-prescribing health insights are reported
- • Drug response is also influenced by age, organ function, diet, and co-medications
- • Rare or novel variants may not be captured by the targeted panel
- • Guidelines evolve — results should be re-interpreted against current CPIC guidance over time
Process and Timeline
Order Kit
Request your saliva collection kit
Provide Sample
Collect and return your saliva sample
PGx Genotyping
Targeted pharmacogenomic panel run
Report Ready
View prescribing guidance (5–6 weeks)
Pricing
PGx vs Lifestyle vs WGS
| Aspect | PGx | GSA v3 (Lifestyle) | WGS 30x |
|---|---|---|---|
| Focus | Drug response only | Lifestyle & wellness | Clinical & medical |
| Method | Targeted PGx panel | SNP genotyping array | Full genome sequencing |
| Guidance source | CPIC / PharmGKB | Trait literature | ClinVar / ACMG |
| Cost | From £228.99 | From £228.99 | £599 |
See also: Lifestyle Genetic Test · Whole Genome Sequencing
Provider & Counselling
Pharmacogenomic testing is provided by Cambridge Genetics Ltd. Visit www.cambridgegenetics.co.uk for more information.
Optional pharmacogenomic counselling is available for £150 — a qualified counsellor can help interpret results in the context of your current and future medications.
Ready to get started?
Sign up to create a study and add optional pharmacogenomic testing for your participants.